GlassScriptPhysician profile
Stephen L Cullen
NPI 1760456305
$3,275.49
in general payments reported to CMS, 2019-2025
36 companies · $656 in 2025
The $656 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $159 · 2021: $50.80 · 2022: $621 · 2023: $804 · 2024: $810 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,269.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $750.78 | 2022-2025 | Qulipta, Linzess, Viberzi |
| Amgen INC. | $367.18 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $314.23 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $220.07 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $159.21 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $148.05 | 2020-2024 | Jornay Pm |
| Corium, LLC | $127.22 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $116.97 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $110.41 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.73 | 2023-2025 | Caplyta |
| Alkermes, INC. | $83.13 | 2021-2023 | Lybalvi, Aristada |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.27 | 2022-2024 | Xifaxan, Trulance |
| Abiomed | $54.28 | 2024-2025 | Impella |
| Glaxosmithkline, LLC. | $53.06 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.32 | 2023-2025 | Jardiance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $46.22 | 2020-2024 | Capvaxive, Vaxneuvance, Gardasil |
| Idorsia Pharmaceuticals US INC | $45.02 | 2023-2024 | Quviviq |
| Lundbeck LLC | $41.99 | 2024 | Rexulti |
| Allergan, INC. | $37.89 | 2019-2020 | |
| Abbott Laboratories | $35.90 | 2023 | Freestyle Libre 3 |
| Collegium Pharmaceutical, INC. | $35.16 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $32.58 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $32.16 | 2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $30.45 | 2022-2023 | Fasenra |
| Amarin Pharma, INC. | $27.49 | 2019 | |
| Phathom Pharmaceuticals, INC. | $20.42 | 2025 | Voquezna |
| Sonex Health, INC. | $20.03 | 2025 | Sx-One Microknife |
| Biohaven Pharmaceutical Holding Company LTD. | $19.74 | 2022 | |
| Biogen, INC. | $17.94 | 2025 | Zurzuvae |
| Teleflex LLC | $17.01 | 2023 | Urolift |
| Bayer Healthcare Pharmaceuticals INC. | $15.71 | 2022 | |
| Sanofi Pasteur INC. | $15.59 | 2023 | |
| Amneal Pharmaceuticals LLC | $15.19 | 2023 | Unithroid |
| Dexcom, INC. | $14.31 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $13.23 | 2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Cullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.